The correlation Between Vitamin D Metabolite Levels With Relapse Rate And Disability In Multiple Sclerosis by Hussein, Hussein Mohamad et al.
Journal of Biology, Agriculture and Healthcare
ISSN 2224-3208 (Paper)  ISSN 2225
Vol 2, No.11, 2012 
 
 
The correlation Between Vitamin D Metabolite Levels With Relapse 
Rate And Disability In Multiple Sclerosis
Hussein Mohamad Hussein1, Nabiel Abdel
* E-mail of the corresponding author
Abstract 
Background: Multiple sclerosis is a major cause of disability in young a
protective effect of Vitamin D on multiple sclerosis is supported by the reduced risk associated with sun exposure and use of
Vitamin D supplements. Moreover, high circulating levels of Vitamin D have be
Objectives: The aim of this study is to clarify the relationship between vitamin D metabolite level and disability and relapse rate 
in multiple sclerosis. Methods: Fifty four Multiple sclerosis
sex and same geographical areas,35 (64.8 %) patients were with relapsing remitting type,9 (16.6 %) patients were primary 
progressive type and 10 (18.6 %) patients were secondary progressive typ
demyelinated neurological diseases including 18 with chronic inflammatory demyelinating polyneuropathy, 6 were Gillian Barrie
syndrome and 4 were acute demyelinating encephalomyelitis, and the remaining
multiple sclerosis patients and controls are subjected to assessment of 25(OH) D serum level by RIA.
statistically significant difference between patients and controls, also very high stat
patients, and disability and relapse rate                                               .                                    
Conclusion: There is an important role of vitamin D in outcome of multiple sclerosis and the relapsing rate of the relapsing 
remitting type 
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1. Introduction 
In the Multiple sclerosis (MS) is a major caus
MS are high because of its long duration, the early loss of productivity, the need for assistance in activities of daily 
living and the use of immunomodulatory treatments and multidisciplina
considered a hereditary disease. However, a number of 
developing the disease.2,3 Although genetic susceptibility explains the clustering of MS within families, it cannot 
fully explain the geographical variations in MS frequency and the changes in risk that occur with migrat
support the action of strong environmental factors. Different environmental factors, both of infectious and non 
infectious origin have been proposed as risk factors for MS,
immunomodulator, and several studies have shown that administration of the biologically active 1, 
25-dihydroxyvitamin D prevents experimental autoimmune encephalomyelitis (EAE) onset and progression in mice. 
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Also the protective effect of Vitamin D on multiple sclerosis i
exposure and use of Vitamin D supplements. Moreover, high circulating levels of Vitamin D have been associated 
with lower risk of multiple sclerosis.
and the main MS-linked HLA-DRB1*1501 allele and evidence showing that vitamin D levels are significantly lower 
in patients with MS as compared to controls. Direct genomic signaling by active vitamin D
through the vitamin D receptor (VDR), which is present in multiple cells of the immune system as well as in 
neurons and glial cells in the human brain. Activation of the VDR by vitamin D stimulates a shift from 
pro-inflammatory T-helper cell-1 (Th1) responses to anti
concentration of 25(OH) D is the best indicato
that obtained from food and supplements and has a fairly long circulating half
circulating 1,25(OH)2D is generally not a good indicator of vitamin D status 
hours and serum concentrations are closely regulated by parathyroid hormone, calcium, and phosphate. Levels of 
1,25(OH)2D do not typically decrease until vitamin D deficiency is severe.
2. Patients and Methods 
According to line of treatment 43 (79.7 %) patients were treated by corticosteroids, 7 (13 %) patients treated 
by disease modifying drugs other than corticosteroids, 3 (5.5 %) patients received combined treatment in the form of 
corticosteroids and another disease modifying agent, and one (1.8 %) patient received no specific treatment. The 
following patients were excluded from the study: Patients with decreased serum albumin, or receiving 
anticonvulsants, those with advanced renal disease, mal
patients received vitamin D. The control were divided into 2 subgroups: (A) including 28 patients with demyelinting 
neurological diseases other than MS including 18 patients with Chronic Inflammatory Demyelintin
Polyradiculoneuropathy (CIDP), with a mean duration  ± SD of 
neurophysiological studies and no significantly related cervical MRI findings, 6 patients with Gillian Barrie 
Syndrome (GBS), with a mean duration  ±
neurophysiologic studies and  CSF findings and 4 patients with ADEM Acute Disseminated Encephalomyelitis 
(ADEM), with a mean duration  ± SD ( 4.5 ± 1.3) months, diagnosed clinically and supported b
subgroup (B) including 42 healthy subjects. The patients were subjected to a full medical history taking, full 
neurological examination, and assessment of the patient disability state using the Expanded Disability Status Scale 
(EDSS). All participants (cases and controls) were underwent CBC, liver and renal function tests, stool analysis, 
serum albumin and assessment of the Serum vitamin D (25 hydroxyvitamin D) which was done using the 
Radio-Immune-Assay (RIA) performed in the Hormone assay
relationship between serum level of 25 hydroxyvitamin D and clinical MS severity, disability as expressed by 
EDSS-score and MS subtypes. Data were collected and statistically analyzed. Statistics were 
Epi - info. Software, version 6.04. A word processing, data base and statistics program (WHO, 2001).      
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3. Results 
 
In this study, regarding the 25(OH) D serum levels and gender of the patient
results showed in table (1):  
Table (1): 25(OH) D serum levels and gender of the patients and controls
 
Case group 
 
controls 
 
Diseased 
 
Healthy 
Relation of 25(OH)D levels to sex difference appear to be with no statistical significance in both MS and control 
groups, but with very high statistical significance in  healthy control and be of low lev
There is a mild positive correlation (Correlation Coef= 0.1), between duration of illness in years and disease 
severity as expressed by EDSS with no statistical significance, as shown in table (
Table (2): relation between duration of i
EDSSDisease duration 
4.09±1.93.8±2.9 
 
          As regard comparison of 25(OH)D  serum levels between case and control groups, the result showed in 
table (3) 
  
                                        
-093X (Online) 
89 
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Sex (OH)D mean ± SD 
F 33 ± 21 
M 34.3 ± 24.4, 
F 54.1 ± 17.2 
M 49.3 ± 19.7, 
F 49.4 ± 11.4 
M 86±11.4 
els in females.
2): 
llness in MS and EDSS 
Correlation Coef.  
0.1  
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0.5 
0.000 
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 Table (3): The serum level of 25(OH
Very high statistical significance between the patient and control groups and appear to be lower in case group. 
  The comparison of 25(OH)D levels and status in both case and control groups subtypes, the results showed in 
table (4). 
Table (4):25(OH)D  serum level and status
 Su
bt
yp
es
 
 gr
o
u
p 
ty
pe
// 
Ite
m
 
 
Total 
 
 
 
Patient group 
(MS) 
RRMS 
 
PPMS 
 
SPMS 
Total 
 
 
 
Diseased control 
 
 
CIDP 
 
GBS 
 
ADEM 
 
Diseased control, 25(OH)D , Mean 
 
Comparative group 
 
P value 
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)D  in the case and control groups.  
 in different groups        
 
25(OH) D status:
 
P 
v
al
u
e 
 
 25
 
(O
H
) 
M
ea
n
±
SD
 
n
u
m
be
r  
deficient 
21 
0.
01
6 
33.3±21.7 54 
10 39.3±23.6 35 
6 19.6±7.4 9 
5 25.2±14.6 10 
0.000
 
P 
0 
0.
00
0 
52.7±17.7 28 
0 59.5±1.8 18 
0 42.7±10.7 6 
0 78.4±11.1 4 
 
 
P 
Patient group (MS) 
25(OH)D , Mean ± SD: 33.3 ± 21.7 
Healthy control, 25(OH)D , Mean ± SD: 59.9 
± 21.4
 
± SD: 52.7 ± 17.7 
0.0000.000 
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Norm. 
 
Insuff. 
11 22 
11 14 
0 3 
0 5 
0.000 0.000  
14 14 
4 14 
6 0 
4 0 
0.7 --- 
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Healthy control 
 
 
   For comparison of 25(OH)D levels between each MS subtypes and control group (healthy and diseased), the 
results shown in table (5).  
Table (5) Comparison of 25(OH)D levels in each MS subtypes to controls
RRMS (39.3±23.6)MS subtype 
 
Diseased 
control 
Comp. group 
 
 
52.7±17.7 
25(OH)D, 
mean ± SD 
 
 
0.3 
 
P value 
 
Twenty five (OH)D levels is significantly lower  in MS subtypes compared to the  controls.  
As regard comparison between 25(OH)D levels and MS severity assessed by EDSS, the results showed in table (
Table (6): 25(OH)D  levels in relation to EDSS 
No. of cases 
EDSS,  Mean ± SD 
 
25(OH)D  Mean ± SD 
 
Very high significant negative relation between 25(OH)D  serum levels and 
score                 
  In MS group, RRMS subtype, with 19 patient in relapse and 16 patient in remission, the comparison between 
25(OH)D levels in patients during relapse and those during remission, table (
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59.9±21.4 
 
42 
0.000
 
P 
:   
SPMS (25.2±14.6)PPMS (19.6±7.4)  
Diseased 
control
Healthy 
control 
Diseased 
control 
Healthy 
control 
 
52.7±17.7
 
59.9±21.4 
 
52.7±17.7 
 
59.9±21.4 
 
0.0002
 
0.0001 
 
0.0001 
 
0.0001 
 
25 (46.3%)     ≥ 
4 
29 (53.7%) 
 <4 
6±1.2 2.5±0.5 
15±4.9 47±14.3 
disease severity as expressed in EDSS 
7). 
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Healthy control 
 
 
59.9±21.4  
 
0.0001  
 
6).  
P value 
0.000 
0.000 
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Table (7): 25(OH)D  levels during relapse and remission
Total (35) 
 
No. of cases 
 
 
39.3±23.6 
25(OH)D  
Mean ± SD 
The serum levels of 25(OH)D  is significantly lower during relapse than remis
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Remission (n=16) Relapse (n= 19) 
 
31.4±20.9 
 
29.5±23.6 
sion. 
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Figure (1): correlation between MS duration 
and EDSS 
There is mild positive correlation (P=0.45), 
between duration of  illness in years and disease 
severity assessed by EDSS, with no statistical 
significance (P=0.45). 
 
Figure (3): correlation between 25(OH) D 
levels and age of diseased controls.
 
There is a strong negative correlations between 
vitamin D levels and age of participants, with a 
very high statistical significance (P=0.000).
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Figure (2): correlation between 25(OH) D levels 
and age of MS patients.
There is a negligible negative correlation between 
vitamin D levels and age of participants, with no 
statistical significance (P=0.8). 
  
 
Figure (4): correlation between 25(OH) D levels 
and age of healthy controls.
There is a strong negative correlatio
vitamin D levels and age of participants, with a 
very high statistical significance (P=0.000). 
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Fig. (5) Correlation between disease duration 
in MS patients and EDSS. 
There is a  moderate positive correlation 
between disease duration in MS patients and 
disease severity assessed by EDSS, with statistical 
insignificance  (P=0.1). 
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Fig. (6) Correlation between disease duration in 
MS patients and D levels. 
There is a moderate negative correlation between 
disease duration in MS patients and vitamin D 
serum levels, with statistical insignificance  
(P=0.1) 
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3.3Discussion 
In the studied subjects the patients were including 39 female  with 25(OH)D mean ± SD of  33 ± 21, and 15 male 
with 25(OH)D mean ± SD of  34.3 ± 24.4, t
in females than in males. In healthy controls the 25(OH)D levels were less in females than in males. These results are 
in agreement with El-Ghoneimy, et al
between female and male, and not in agreement with the study of 
found that women with MS had significantly higher 25(OH) concentrations than men with MS. In the studied 
patients, the 25(OH)D serum level was lower than that of the controls, these results are in concordance with the study 
of  Correale et al5 who found that, MS population had lower 25(OH) D than controls, and in concordance with the 
study of  Lucas et al17 and the study of  
low 25(OH)D levels than controls. However the study of  Kragt et al
(OH) D and MS in women, also the study of  Barnes et al
women with MS,  but in our study we found that 25 vitamin D deficiency was evident in both women and men. 
Regarding to diseases subtypes,  25(OH)D deficiency was more evident in PPMS, compared to  SPMS and RRMS, 
these results are in accordance with Smolders et al
significantly lower in the progressive forms of
disagreement with Correale et al5 who found no signific
patients with healthy controls, but in our study we found that 25(OH)D levels were more deficient in PPMS than 
other MS subtypes and controls. The serum level of 25(OH)D in the studied patients in relat
determined by EDSS scale score, there was a very high significant negative correlation in all MS patients, and was 
being more evident in PPMS and RRMS. These results are in accordance with  
and van der Mei et al21 who found that, lower levels of 25(OH) were associated with higher EDSS and the study of  
Smolders, et al7 who found that, 25(OH)D concentrations were inversely associated with disease severity Score. 
These results are disagree with the study of El
correlation between 25(OH)D level and disease severity, as assessed by EDSS, but in our study we found that, a very 
high statistically significant negative correlation between 25(OH)D level and disease severity, as assessed by EDSS, 
this may be due to exclusion of vitamin D medicated patients in our study. There was a very significant negative 
correlation between the 25(OH)D serum levels and the relapse rate. This relation is in consistent with the study 
Smolders et al7 and Smolders22 who found that, Serum 25(OH) D levels were associated inversely with relapse rate, 
also the 25(OH)D serum levels are low during relapse than in remission, these results are consistent with the study of 
Correale et al5 who found that, significantly lower levels of both vitamin D metabolites 25(OH)D in patients during 
exacerbation than patients during remission. Also our results were in accordance with SoiluHanninen
that 25(OH) D serum levels were s
remission. 
5. Conclusion 
The serum levels of 25(OH) D are lower in MS patients with a negative correlation when compared to the 
severity of the disease and to the relapsing rate in t
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